DEP-Trastuzumab, page-9

I doubt Roche is working on Her2-DEP, cause Kadcyla and Herceptin  are Roche products. SPL named directly these one on their study which may need the Roche acceptance. So we might see the announcement phase 1 clinical trial of Her2-DEP later this year or next year. Like Genentech (trastuzumab), Roche tends to acquire small start-up company with any cost as they need DEP desperately to complete targeted therapy.
Sure SPL knew this, they sold everything else to bet on DEP platform. If we win, the company is at least 40 times bigger